{"id":14182,"date":"2021-04-28T10:38:32","date_gmt":"2021-04-28T08:38:32","guid":{"rendered":"https:\/\/ggba.swiss\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/"},"modified":"2023-07-04T13:40:15","modified_gmt":"2023-07-04T11:40:15","slug":"adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/","title":{"rendered":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA"},"content":{"rendered":"<p>Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in the United States, is a rapidly progressing, aggressive disease that is heterogeneous with multiple subtypes. More than 40% of first-line DLBCL treatments fail.<\/p>\n<p><a href=\"https:\/\/adctherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">ADC Therapeutics<\/a>\u2019 late-stage candidate <a href=\"https:\/\/zynlontahcp.com\/\" target=\"_blank\" rel=\"noopener\">ZYNLONTA<\/a> is the first and only CD19-targeted antibody-drug conjugate (ADC) which can be used as a single-agent treatment for adult patients.<\/p>\n<p>Based on the overall positive response rates obtained during clinical trials, ZYNLONTA has been granted accelerated approval by the FDA (U.S. Food and Drug Administration).<\/p>\n<h4>An important milestone for ADC Therapeutics<\/h4>\n<p>With the approval, ZYNLONTA will be commercially available in the United States shortly. The company based at the <a href=\"https:\/\/www.biopole.ch\/\" target=\"_blank\" rel=\"noopener\">Biop\u00f4le<\/a> in Epalinges (canton of Vaud) has also launched the Advancing Patient Support Program, a comprehensive patient support program offering financial assistance, ongoing education and other resources to eligible patients who are prescribed ZYNLONTA.\u00a0<\/p>\n<p>\u201cThe FDA approval of ZYNLONTA is an exciting advancement for patients with r\/r DLBCL and a transformational event for ADC Therapeutics,\u201d said Chris Martin, CEO of ADC Therapeutics. \u201cWe extend our deepest gratitude to the patients who participated in our LOTIS-1 and LOTIS-2 clinical trials, their families, the study investigators and our employees, as their commitment made this important milestone possible.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oncology biotechnology company ADC Therapeutics has received the first FDA approval for ZYNLONTA, its lead drug candidate for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.<\/p>\n","protected":false},"author":3,"featured_media":14183,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,883],"class_list":["post-14182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"Oncology biotechnology company ADC Therapeutics has received the first FDA approval for ZYNLONTA, its lead drug candidate for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T08:38:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:40:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA\",\"datePublished\":\"2021-04-28T08:38:32+00:00\",\"dateModified\":\"2023-07-04T11:40:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\"},\"wordCount\":219,\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg\",\"keywords\":[\"Biotech\",\"Oncology\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\",\"name\":\"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg\",\"datePublished\":\"2021-04-28T08:38:32+00:00\",\"dateModified\":\"2023-07-04T11:40:15+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area","og_description":"Oncology biotechnology company ADC Therapeutics has received the first FDA approval for ZYNLONTA, its lead drug candidate for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.","og_url":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2021-04-28T08:38:32+00:00","article_modified_time":"2023-07-04T11:40:15+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"mathieu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#article","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA","datePublished":"2021-04-28T08:38:32+00:00","dateModified":"2023-07-04T11:40:15+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/"},"wordCount":219,"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg","keywords":["Biotech","Oncology"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/","url":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/","name":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage"},"image":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg","datePublished":"2021-04-28T08:38:32+00:00","dateModified":"2023-07-04T11:40:15+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-4.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/staging.ggba.swiss\/en\/adc-therapeutics-receives-fda-approval-for-its-lymphoma-cancer-treatment-zynlonta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics receives FDA approval for its lymphoma cancer treatment ZYNLONTA"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/en\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=14182"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14182\/revisions"}],"predecessor-version":[{"id":16921,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/14182\/revisions\/16921"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/14183"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=14182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=14182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=14182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}